Fabian Kiessling (born 16 August 1972) is a German radiologist, university lecturer, and author as well as a scientist in the field of molecular imaging.
From 2001 he worked in the Dept. of Oncological Diagnostics and Therapy at the German Cancer Research Center (DKFZ) in Heidelberg and stayed there as an intern until 2002.
In 2003 he moved to the Dept. of Oncology at the Thorax Clinic Heidelberg and in parallel became head of the Molecular Diagnostics group in the Dept. of Medical Physics in Radiology at the DKFZ.
In 2006, he became the Junior Group Leader for 'Molecular Imaging' at the DKFZ and habilitated in Experimental Radiology at the Heidelberg University.
2007 he completed his education as a medical specialist in diagnostic radiology.
In March 2008 he was appointed as full professor and director of the Institute for Experimental Molecular Imaging (ExMI) at RWTH Aachen (Rheinisch-Westfälische Technische Hochschule Aachen). He is also one of the directors of the RWTH Helmholtz Institute for Biomedical Engineering.
Boards and Chairs
2005-2012 - Speaker of the section Molecular Imaging of the working group Methodology and Research of the Deutsche Röntgengesellschaft
2008-2012 - chairman of the abovementioned working group
2012-onwards - Served in the council of European Society for Molecular Imaging (ESMI)
2014-2015 - Chairman of the “Molecular Imaging Subcommittee” of the European Society of Radiology
2016 - Program chair of the World Molecular Imaging Congress in New York
2018 - Member of the Board of Trustees of the World Molecular Imaging Society (WMIS)
2023-2024 - President of the ESMI (European Society for Molecular Imaging)
Research
The research of Fabian Kiessling focusses on the development of new imaging methods and probes, with a particular focus on oncology and diseases that go along with angiogenesis and vascular remodeling. He worked on the imaging technique volumetric area detector computed tomography[2] and published the new ultrasound technique Motion Model Ultrasound Localization Microscopy together with his colleague Georg Schmitz. The ultrasound technique was preclinically tested and used in a first clinical application.[3] Both methods allow non-invasive imaging of hair-thin blood vessels in tumors and other tissues. In his translational research, imaging-guided therapy plays an important role including the investigation of biological barriers for drug delivery and the development of strategies to overcome these barriers by the use of nanomedicines, drug delivery systems, and other therapeutics.
T Lammers, F Kiessling, WE Hennink, G Storm/ Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress. Journal of controlled release 161 (2), 175-187 (2012).
T Lammers, S Aime, WE Hennink, G Storm, F Kiessling. Theranostic Nanomedicine. Accounts of chemical research 44 (10), 1029-1038 (2011)